Intellia Therapeutics, Inc. (NTLA)

149.14
NASDAQ
Prev Close 155.26
Day Low/High 148.50 / 154.15
52 Wk Low/High 18.81 / 202.73
Exchange NASDAQ
Shares Outstanding 73.49B
Market Cap 11.41B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Intellia Therapeutics Busts Out of Resistance on Positive Trial News

Intellia Therapeutics Busts Out of Resistance on Positive Trial News

The news sent shares of the genome editing company skyward after the stock had been basing for months.

Jim Cramer: Monday's Market Is One of the Most Mind-Blowing I've Seen

Jim Cramer: Monday's Market Is One of the Most Mind-Blowing I've Seen

Buyers make or break companies with their voting or buying or betting. Somedays it's all that matters.

Cutting Edge Intellia Therapeutics Charts Are Bullish

Cutting Edge Intellia Therapeutics Charts Are Bullish

Here are our price targets for now.

4 ETFs on the Cutting Edge: Data, Genomics, Robotics and Fintech

4 ETFs on the Cutting Edge: Data, Genomics, Robotics and Fintech

These ARK Funds family funds are focused on new opportunities and investment themes.

These Intriguing ETFs Are on the Cutting Edge of Disruptive Technologies

These Intriguing ETFs Are on the Cutting Edge of Disruptive Technologies

Ark Invest has developed a series of specialized exchange-traded funds that own shares in companies involved in 'disruptive innovation.'

Tesla, 'Gene Editing' Stocks Under Pressure

Not much movement in the markets so far today as the trading week begins. Major indices are in a narrow range and have fluctuated between slight losses and negligible gains throughout this morning. Tesla  is off over 3% following up on some weakness...

Intellia Therapeutics Has Upside in Its DNA

Intellia Therapeutics Has Upside in Its DNA

The setup here is appealing enough to take a small, aggressive shot on the long side.

Novocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers

Novocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers

Oncology firm released results that show increased compliance with Optune predicted increased survival in patients with glioblastoma, a form of brain cancer.

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.

Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers

Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers

The Cambridge, Mass.-based company and Mylan said that M834, a proposed biosimilar of Orencia (abatacept), did not achieve its primary pharmacokinetic endpoints in a Phase 1 study.

Intellia Therapeutics Is Worth Trading Right Now

Intellia Therapeutics Is Worth Trading Right Now

Look for NTLA to go higher from here.